This blog is one of the edition of Top 10 Market Leaders in Dhaka Stock Exchange: Fundamentals & Insights series. In this series I am trying to get a holistic overview for each top 10 companies in Dhaka stock Exchange.
Beximco Pharmaceuticals Ltd. (BXPHARMA): Bangladesh’s Global Pharma Pioneer.
Beximco Pharmaceuticals Ltd (BXPHARMA) – Market Insights, Financials & Global Reach.
Dive into Beximco Pharmaceuticals (BXPHARMA): company origins, financial performance, export milestones, DSE stock overview, and strategic outlook in Bangladesh’s pharma industry.
1. Origins & Evolution
- Founded: 1976; began operations in 1980 under licensing from Bayer AG and Upjohn Inc.
- Milestone: First Bangladeshi pharmaceutical firm to export to the U.S.—a groundbreaking stride for local pharma.
- Acquisition: In October 2021, Beximco Pharma secured a controlling 54.6% stake in Sanofi Bangladesh Ltd.
2. Business Scope & Capabilities
- Manufactures generic formulations and active pharmaceutical ingredients (APIs). Offers wide therapeutic coverage: from cardiovascular and oncology to inhalers and IV fluids.
- Capabilities: Offers diverse dosage forms—tablets, injectables, powders, inhalers, and nasal sprays. Serves both domestic market and global exports.
3. Financial Snapshot & DSE Metrics
| Metric | Value |
|---|---|
| Stock Price | ৳130.70 (as of Aug 28, 2025) |
| Market Cap | ৳58.31 Billion |
| Revenue (TTM) | ৳46.34 Billion |
| Net Income (TTM) | ৳6.35 Billion |
| EPS (TTM) | ৳14.24 |
| P/E Ratio | ~9.2× (forward P/E ~8.9×) |
| Dividend Yield | 4.0 BDT / ~3.06% |
| 52-Week Range | ৳64.20 – ৳135.20 |
| Volatility (Weekly) | ~5.7%, slightly above industry avg 5.2% |
| Return (1Y) | ~71.5%, outperforming industry (-2.4%) & market (-9.4%) |
4. Investor Highlights & Strategic Strengths
- Strong financial performance: Robust net income, double-digit EPS, and moderate P/E offer both growth and value.
- Global export credibility: Pioneering U.S. exports and Sanofi Bangladesh acquisition enhance global stature.
- Consistent dividend: 3%+ yield adds investor appeal.
- Share price rally: Surged over 70% last year, a standout compared to peers.
5. Risks & Considerations
- Regulatory environment: Operating globally means navigating stringent compliance—particularly in developed markets like the U.S.
- Competition: Faces domestic and regional pharma players, plus pricing pressure from generic producers.
- Valuation watch: Strong recent performance can raise valuation concerns—though current P/E remains reasonable.
6. FAQ
Q1: What is Beximco Pharma’s ticker on DSE?
A: BXPHARMA
Q2: What was their strategic move in 2021?
A: Acquired 54.6% of Sanofi Bangladesh Ltd., expanding product portfolio and reach.
Q3: How have shareholders been rewarded?
A: Through consistent dividends ৳14.24 and strong past-year returns (+71.5%).
Q4: What makes BXPHARMA outperform the market?
A: Its export focus, brand partnerships, acquisition strategy, and strong earnings growth.
7. Conclusion
Beximco Pharmaceuticals Ltd. (BXPHARMA) stands as a pillar in Bangladesh’s pharmaceutical sector—blending history, export leadership, and solid financials. Investors seeking a combination of growth, dividends, and global credibility will find BXPHARMA compelling—especially at a sub-10 P/E ratio and continued earnings momentum.
